AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data
Executive Summary
The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says
You may also be interested in...
OIG To Study AWP Prices For Physician-Administered Drugs
The HHS Office of the Inspector General will conduct studies of AWP with the aim of allowing state Medicaid programs to reimburse physician-administered drugs at a lower price
OIG To Study AWP Prices For Physician-Administered Drugs
The HHS Office of the Inspector General will conduct studies of AWP with the aim of allowing state Medicaid programs to reimburse physician-administered drugs at a lower price
AWP Reform: Competitive Bidding Option Could Save The Most, CMS Says
The Centers for Medicare & Medicaid Services' proposed rule for Medicare AWP reform places the potential for the greatest cost savings on the approach taken in the House Medicare prescription drug bill